510(k) device
iVue
Optovue, Inc. · Tomography, Optical Coherence (OBO, Class II) · First FDA decision Apr 22, 2010, newest Jun 9, 2017GlaucomaMacular degeneration and retinal disease
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
2
510(k) pathway
Device trials
5
Naming "iVue"
MAUDE reports
0
Brand "iVue", since 2015
PubMed studies
53
Mentioning "iVue"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing iVue
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 2 of 2 decisions filed under this name.
- iVue510(k)
K163475 · Decided Jun 9, 2017 · 179 days after receipt
Device type: Tomography, Optical Coherence (OBO) · Ophthalmology
- IVUE, MODEL 100510(k)
K091404 · Decided Apr 22, 2010 · 345 days after receipt
Device type: Tomography, Optical Coherence (OBO) · Ophthalmology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "iVue", any status and sponsor, newest update first.
- Clinical Study of the Optic Disc ParametersPivotal-lookingCompleted
Topcon Medical Systems, Inc.Not on our public-company list
NCT02277119 · 109 participants · Start Oct 2014 · Primary completion Jan 2015
Device: Maestro; iVue · For: Normal Healthy Subjects With No Known Ocular Diseases; Glaucomatous Eyes; Eyes With Retinal Diseases
Sites: Pomona, California; New York, New York
Topcon Medical Systems, Inc.Not on our public-company list
NCT02376868 · 101 participants · Start May 2015 · Primary completion Sep 2015
Device: 3D OCT-1 Maestro; iVue · For: Normal Healthy Subjects With No Known Ocular Diseases; Glaucomatous Eyes; Eyes With Retinal Diseases
Sites: Pomona, California
Kowa Research Institute, Inc.Not on our public-company list
NCT03505567 · 12 participants · Start Apr 21, 2018 · Primary completion Sep 1, 2018
Device: KOWA OCT Bi-µ; Optovue iVue 100 · For: Glaucoma; Retinal Disease; Healthy
Sites: Andover, Massachusetts
2 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "iVue", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code OBO
13 reports: 4 malfunction, 9 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-0024-2013 · Started Sep 7, 2012 · Posted by FDA Oct 9, 2012
Reason given: Devices labeled for an intended use not included in the existing 510(k) or PMA. Specifically, "The Retina" poster provided with the systems, and the book "RETINAL OCT Analysis and Interpretation Method" by Bruno Lumbroso and Marco Rispoli which are not labeled within 51O(k) cleared product description.
Cause as FDA categorized it: No Marketing Application · Device type: Tomography, Optical Coherence (OBO)
Z-1004-2011 · Started Jul 20, 2010 · Posted by FDA Feb 1, 2011
Reason given: Use of the CAM attachment may result in a positioning anomaly and mistreatment in the eyes of the patient.
Cause as FDA categorized it: Software design (manufacturing process) · Device type: System, Imaging, Optical Coherence Tomography (Oct) (NQQ)
Published research
The most relevant PubMed records for "iVue"[tiab]. The summary above synthesizes these.
- Use of Optical Coherence Tomography by Nonexpert Personnel as a Screening Approach for Glaucoma.
Liu MM, Cho C, Jefferys JL, et al. · J Glaucoma · 2018Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Comparison of two spectral domain optical coherence tomography devices for angle-closure assessment.
Quek DT, Narayanaswamy AK, Tun TA, et al. · Invest Ophthalmol Vis Sci · 2012Comparative Study, Research Support, Non-U.S. Gov't
- Diagnostic Accuracy of Technologies for Glaucoma Case-Finding in a Community Setting.
Dabasia PL, Fidalgo BR, Edgar DF, et al. · Ophthalmology · 2015Observational Study, Research Support, Non-U.S. Gov't
- Repeatability and Reproducibility of Corneal Epithelial Thickness Mapping With Spectral-Domain Optical Coherence Tomography in Normal and Diseased Cornea Eyes.
Sella R, Zangwill LM, Weinreb RN, et al. · Am J Ophthalmol · 2019Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
- Evaluation of Agreement between HRT III and iVue OCT in Glaucoma and Ocular Hypertension Patients.
Perdicchi A, Iester M, Iacovello D, et al. · J Ophthalmol · 2015
- Identification of anterior chamber angle parameters with a portable SD-OCT device compared to a non-portable SD-OCT.
Akil H, Marion K, Dastiridou A, et al. · Int Ophthalmol · 2017
- Retinal Nerve Fiber Layer Thickness and Rim Area Profiles in Asians: Pooled Analysis from the Asian Eye Epidemiology Consortium.
Majithia S, Tham YC, Chong CCY, et al. · Ophthalmology · 2022Research Support, Non-U.S. Gov't
- Repeatability and reproducibility of retinal nerve fibre layer thickness measurements with the iVue-100 optical coherence tomographer.
Rampersad N, Hansraj R · Afr Health Sci · 2018Observational Study
- Application of anterior segment optical coherence tomography in glaucoma.
Sharma R, Sharma A, Arora T, et al. · Surv Ophthalmol · 2014Review
- Efficacy and tolerability of polyvinylpyrrolidone-iodine 0.6% treatment in adenoviral keratoconjunctivitis: a Prospective Randomized Controlled Study.
Ricciardelli G, Giannaccare G, Di Zazzo A, et al. · Eye (Lond) · 2022Randomized Controlled Trial
- Prospective evaluation of optical coherence tomography for disease detection in the Casey mobile eye clinic.
Tan O, Chen A, Li Y, et al. · Exp Biol Med (Maywood) · 2021Evaluation Study, Research Support, N.I.H., Extramural
- Central Macular Thickness in Diabetic Patients: A Sex-based Analysis.
Arthur E, Young SB, Elsner AE, et al. · Optom Vis Sci · 2019Comparative Study, Research Support, N.I.H., Extramural
Other devices of this type
Also filed under product code OBO.
- SPECTRALIS HRA+OCT and variantsHeidelberg Engineering GmbH · 510(k) 2026
- CIRRUS HD-OCT Model 6000Carl Zeiss Meditec, Inc. · 510(k) 2024
- AnterionHeidelberg Engineering GmbH · 510(k) 2026
- Spectralis HRA + OCT and variantsHeidelberg Engineering GmbH · 510(k) 2018
- 3D OPTICAL COHERENCE TOMOGRAPHY 3D OCT-1 (type: Maestro2)Topcon Corporation · 510(k) 2024
- Tomey Cornea/Anterior Segment OCT (CASIA2)Tomey Corporation · 510(k) 2025
- P200TE (A10700)Optos Plc. · 510(k) 2024
- RESCAN 700, CALLISTO eyeCarl Zeiss Meditec, AG · 510(k) 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.